

CURRICULUM VITAE

SUNIL S. Dhawan, MD

Center for Dermatology, Cosmetic and Laser Surgery, Inc, and Center for Dermatology Clinical Research, Inc.

Email- sdhaw@yahoo.com

OFFICE: (510) 797-4111, (408) 957-7676

DATE OF BIRTH: April 17, 1959

PLACE OF BIRTH: London, England

UNDERGRADUATE EDUCATION: San Francisco State University, San Francisco, CA. Graduated Summa Cum Laude, Bachelor of Science in Chemistry, June, 1979. Dean's list for all four years.

MEDICAL EDUCATION: University of Southern California School of Medicine, Los Angeles, CA. M.D. received in May, 1983.

POSTGRADUATE EDUCATION: Resident in Internal Medicine, Mount Zion Hospital and Medical Center, San Francisco, CA, June 1983 - June 1986.

Resident in Dermatology, Mount Sinai Medical Center, Miami Beach, FL, July 1987 - June 1989.

Chief Resident in Dermatology, Mount Sinai Medical Center, Miami Beach, FL, July 1989 - June 1990.

POSITIONS HELD: Principal Investigator, Center for Dermatology Clinical Research Inc., Fremont, CA August 2002 - present.

Private practice in Dermatology and Dermatologic Surgery, Center for Dermatology Medical, Cosmetic and Laser Surgery, Inc., Fremont and Milpitas, CA, July 1990 - present.

Clinical Assistant Professor of Dermatology, Stanford University School of Medicine, Palo Alto, CA, November 1992 - present.

Attending Physician, Department of Internal Medicine and the Division of Emergency Medicine, Mount Zion Hospital and Medical Center, San Francisco, CA, July 1986 - June 1987.

Clinic Physician, Department of Internal Medicine, Kaiser Foundation Hospital, San Francisco, CA, July 1985 - June 1987.

Staff Physician, Access Health Care Centers, San Francisco, CA, July 1986 - June 1987.

Clinic Physician, Department of Internal Medicine, Kaiser Foundation Hospital, South San Francisco, CA, January 1985 - June 1987.

HONORS:

Elected to the Who's Who in the State of California, and United States

Elected to the Outstanding Young Men of America

Recipient of the USC Medical Fellowship for Research

**BOARD
CERTIFICATION:**

Diplomate, American Board of Dermatology, November 1990
Diplomate, American Board of Internal Medicine, September 1986
Diplomate, National Board of Medical Examiners, June 1984

STATE LICENSURE:

California (since 1984)

**PROFESSIONAL
ORGANIZATIONS:**

Fellow, American College of Physicians
Fellow, American Academy of Dermatology
California Medical Association
Alameda-Contra Costa County Medical Association

PUBLICATIONS:

Weitzner JM, Dhawan SS, Rosen LB, et al: Successful therapy of botryomycosis in a patient with AIDS. Journal of the American Academy of Dermatology 21:1312-1314, 1989.

Dhawan SS, Weitzner JM, Zaias N: Vesicular scabies in an adult. Cutis 43:267-268, 1989.

Dhawan SS, Fields, KW: Lichen planus and ulcerative colitis - Is there a relationship? International Journal of Dermatology 28:534, 1989.

Dhawan SS, Nanda VS, Rabinovitz HS: Apocrine adenocarcinoma: A review of the literature. Journal of Dermatologic Surgery and Oncology 16:468-470, 1990.

Goodless DR, Dhawan SS, Wiszniak J, et al: Cutaneous periarteritis nodosa. International Journal of Dermatology 29:611-615, 1990.

Dhawan SS, Pena J., Zaias N: The nail fold in pemphigus vulgaris. Archives of Dermatology, 126:1374-1375, 1990.

Dhawan SS, Jimenez-Acosta F, Popitti R, Barkin JS: Subcutaneous fat necrosis associated with pancreatitis - Histochemical and electron microscopic findings. American Journal of Gastroenterology 85:1025-1028, 1990.

Dhawan SS, Wolf D, Rabinovitz HS: Lentigo maligna - The use of rush permanent sections in therapy. Archives of Dermatology 126:928-930, 1990.

Dhawan SS, Wolf D, Rabinovitz HS: Lentigo maligna - The use of rush permanent sections in therapy. Archives of Dermatology 126:928-930, 1990.

Gmitter TJ, Dhawan SS, Wiszniak J: Cutaneous metastases of colonic adenocarcinoma. Cutis 46:66-68, 1990.

Dhawan SS, Herbst JS, Fields KW: Tender nodules on the legs. Archives of Dermatology 127:247-252, 1991.

Beko E, Pervaiz S, Dhawan SS: Long term follow up of patients with diffuse fasciitis and eosinophilia associated with l-tryptophan ingestion. Cutis 51:266-70, 1993.

Dhawan SS, Blyumin ML, Pearce DJ, Feldman SR: Tazarotene cream (0.1%) in Combination with Betamethasone Valerate Foam (0.12%) for Plaque Type Psoriasis. Journal of Drugs in Dermatology 4:228-230, 2005.

Conley JJ, Nanton J, Dhawan S, Pearce DJ, Feldman SR: Novel Combination Regimens: Biologics and Acetretin for the Treatment of Psoriasis – A Case Series. Journal of Dermatological Treatment 4:1-4, 2006.

Tanghietti E, Dhawan SS, Torok H, Kircik L: Tazarotene 0.11% cream plus clindamycin 1% gel versus tretinoin 0.025% gel plus clindamycin 1% gel in the treatment of facial acne vulgaris. Dermatology Online Journal 13:4, 2007.

21st World Congress of Dermatology. Comparison of the Tolerability and Efficacy of Tazarotene 0.1% cream with clindamycin 1% gel versus tretinoin 0.025% gel with clindamycin 1% gel for the treatment of acne vulgaris. Roster session. Buenos Aires, Argentina: September 30, 2007 – October 5, 2007.

Draeos ZD, Callender V, Young C, Dhawan SS: The Effect of Vehicle Formulation on Acne Medication Tolerability. Cutis, 82: 281-284, 2006

Kircik L, Green L, Thibitot D, Tanghietti E, Wilson D, Dhawan S, Fair L: Comparing a Solubilized benzoyl peroxide gel with benzoyl peroxide/clindamycin. Journal of Drugs in Dermatology : 812-821,2008.

Dhawan, SS. Comparison of two clindamycin 1% - benzoyl peroxide 5% topical gels used once daily in the management of acne vulgaris. Cutis 83: 265-272, 2009.

Dhawan, SS: Tips to Help Your Bottom Line. Healthguard News G:4, 2010.

Tanghietti E, Dhawan SS, Green L, et al: Randomized Comparison of the Safety and Efficacy of Tazarotene 0.1% Cream and Adapalene 0.3% Gel in the Treatment of Patients with at least Moderate Facial Acne Vulgaris. Journal of Drugs in Dermatology. 9:549-558, 2010.

Wheelanct RG, Dhawan SS. Evaluation of Self-Treatment of Mild-Moderate Facial Acne with a Blue Light Treatment System. Journal of Drugs in Dermatology: 10 (7). 329-335, 2011.

Tanghietti E, Dhawan S, Greer L, Ling M et al. Clinical Evidence for the Role of a Topical Anti-Inflammatory Agent in Comedonal Acne: Findings From a Randomized Study of Dapsone Gel 5% in Combination with Tazarotene Cream 0.1% in Patients with Acne Vulgaris. Journal of Drugs in Dermatology. 10(7). 783-792, 2011.

Dhawan SS, Gwajdauskas J. Clindamycin Phosphate 1.2% - Benzoyl Peroxide (5% or 2.5%) plus Tazarotene Cream 0.1% for the Treatment of Acne. Cutis 91. 99-104, 2013.

Tanghietti EA, Doxer JS, Goldberg DJ, Dhawan SS, Fu Y, Berk DR, Ahlwalea G, Alvande N. Topical Oxymelazoline. Hydrochloride II. Effectively Reduces Persistent Facial Erythema of Rosacea on Day 1. Fall Clinical Dermatology Conference. October 12-15, Las Vegas, NV.

Stein-Gold I, Dhawan SS, Weiss J, Draelos ZD, Ellman A. The Efficacy and Safety of FMX101, Minocycline Foam 4Y for the Treatment of Acne Vulgaris: A Pooled Analysis of 2 Phase 3 Studies. Fall Clinical Dermatology Conference. October 12-15. Las Vegas, NV.

Stein-Gold L, Kircik LH, Tying SK, Bruce S, Schlessinger J, Moore A, Dhawan SS, eval. Once-Daily Oral Sarecycline 1.5 mg/kg/day IS Effective, Safe and Well Tolerated for Moderate to Severe Acne Vulgaris: Data From Two Phase 3 Pivotal Studies. Sixth Annual Dermatologic and Aesthetic Surgery International League (DASIL) Congress. October 24-28, 2017, Shanghai, China.

Yoelin S, Dhawan SS, Abushakara S, Vitarella D, Ahmad W, Hasan F. Clinical Development of a Novel Stereotype – E Botulinum Toxin: A Phase 2A Study of EB-001 In Glabellar Lines. The American Society of Dermatologic Surgery Annual Meeting. October 5-8, 2017. Chicago, Illinois.

Stein-Gold L, Dhawan SS, Weiss J, Draelos ZD, Ellman H. FMX 101 4% Minocycline Foam for the Treatment of Acne Vulgaris: Efficacy and Safety From the Open-Label Extension of 2 Phase 3 studies. Winter Clinical Dermatology Conference. January 12-17, 2018, Maui, Hawaii.

Stein-Gold L, Kircik LH, Tyring SK, Bruce S, Schlesinger J, Moore A, Dhawan SS, , Bhaha ND, Green LJ, Gold MH, Schmitz C, Boodhoo TI, Berk DR, Kawkhov A. Once – Daily Oral Sarecycline 1.5 mg/kg/day Is Effective, Safe and Well Tolerated for Moderate to Severe Acne Vulgaris: Data from Two Phase 3 Pivotal Studies. Clinical Dermatology Conference. January 12-17, 2018, Maui, Hawaii.

Tanghietti, EA, Dover JS, Goldberg DJ, Dhawan SS, Fu Y, Berk DR, Ahluwalia GI, Alvandi N. Topical Oxymetazoline Hydrochloride 1% Effectively Reduces Persistent Facial Erythema of Rosacea on Day 1. American Academy of Dermatology National Meeting. March 1-6, 2018, San Diego, CA.

Tanghietti, EA, Dover JS, Goldberg DJ, Dhawan SS, Fu Y, Berk DR, Ahluwalia GI, Alvandi N. Clinically Relevant Reduction in Persistent Facial Erythema of Rosacea on the First Day of Treatment with Oxymetazoline Cream 1%. Journal of Drugs in Dermatology 17. 621-632, 2018.

Dhawan A, Dhawan SS, Vitarella D. The Potential Role of Botulinum Toxin in Improving Superficial Cutaneous Scarring: A Review. Journal of Drugs in Dermatology 17. 956-960, 2018.

Stein-Gold L, Kircik LH, Tyring SK, Bruce S, Schlesinger J, Moore A, Dhawan SS, , Bhaha ND, Green LJ, Gold MH, Schmitz C, Boodhoo TI, Berk DR, Kawkhov A. Once Daily Oral Sarecycline 1.5 mg/kg/day Is Effective for Moderate to Severe Acne Vulgaris: Results from Two Identically Designed, Phase 3, Randomized, Double-Blind Clinical Trials. Journal of Drugs in Dermatology 17. 987 – 999, 2018

Yoelin S, Dhawan SS, Vitarella D, Ahmad, LU, Hasan F, Abushakara S. Safety and Efficacy of EB-001, a Novel Type E Botulinum Toxin in Subjects with Glabellar Frown Lines: Results of a Phase 2, Randomized, Placebo-Controlled Ascending Dose Study. Plastic and Reconstructive Surgery 142. 847-855, 2018.

Stein-Gold L, Dhawan SS, Weiss J, Draelos ZD, Ellman H, Sheart I. A Nasal Topical Minocycline Foam for the Treatment of Moderate-to Severe Acne Vulgaris: Results of two randomized double blind phase 3 studies. Journal of the American Academy of Dermatology 80. 168-178, 2019.

Bissonnette R, Maari C, Forman S, Bhatra N, Lee M, Fowler J, Tying S, Pariser D, Sofen H, Dhawan S, et al. The Oral Janus Kinase/Spleen Tyrosinase Kinase Inhibitor- ASN 002 Demonstrates Efficacy and Improves Associated Systemic Inflammation in Patients with Moderate-Severe Atopic Dermatitis: Results from a Randomized Double Blind Placebo – Controlled Study. British Journal of Dermatology. 181. 733-742, 2019.

Schonfield L, Stein-Gold L, Silverberg N, Raof T, Hooper D, Moore A, Zaiac M, Sullivan T, Kiveck L, Lam T, Dhawan SS, et al. Clinical Safety and Pharmacokinetics of FMX 101 4%. Topical Minocycline Foam in Pediatric Patients for the Treatment of Moderate – Severe Acne Vulgaris. Derm Meeting. July 18-21, Las Vegas, Nevada.

Stein-Gold L, Dhawan SS, Weiss J, Draelos ZD, Ellman H, Stuart I. Open Label Extension Study Evaluating Long Term Safety and Efficacy of FMX 101 4%. Minocycline Foam Moderate – Severe Acne Vulgaris. Journal of Clinical and Aesthetic Dermatology Online Edition. October 2019.

Stein-Gold L, Dhawan SS, Weiss J, Draelos ZD, Ellman H, Stuart I. Fall Clinical Dermatology Conference Poster Session. October 17-20, Las Vegas, Nevada. Above presented at poster session.

Moore A, Cook-Bolden F, Nasir A, Dhawan SS, et al. Once Daily Oral Sarecycline 1.5 mg/kg/day is Effective for Moderate to Severe Acne Vulgaris: Results from 2 Identically Designed Phase 3, Randomized Double-Blind Clinical Trials. ACMP Managed Care Specialty Pharmacy Annual Meeting. March 25-28, San Diego, CA.

**INVITED
PRESENTATIONS:**

Medical Grand Rounds, Mount Zion Hospital and Medical Center: Preoperative medical evaluation of the surgical patient. San Francisco, CA: October 23, 1985.

Pan American Medical Seminar: Acne vulgaris in the adolescent. Mount Sinai Medical Center, Miami Beach, FL: October 21, 1988.

American Physicians Fellowship Annual Midwinter Assembly: Common dermatologic diseases. Hollywood, FL: March 4, 1988.

Gross and Microscopic Symposia, American Academy of Dermatology Annual Meeting: Lichen planus and ulcerative colitis. Washington, DC: December 4, 1988.

The Osler Internal Medicine Review: Common dermatologic diseases. Ft. Lauderdale, FL: September 6, 1989.

Gross and Microscopic Symposia, American Academy of Dermatology Annual Meeting: Subcutaneous fat necrosis associated with pancreatitis. San Francisco, CA: December 3, 1989.

Pediatric Clinic Conference, Alexian Brothers Hospital: Common Pediatric Dermatoses. San Jose, CA: December 7, 1990.

Medical Conference, Washington Hospital: Acne Vulgaris. Fremont, CA: January 25, 1991.

Obstetrical Conference, Washington Hospital: The Dermatoses of Pregnancy. Fremont, CA: February 25, 1991.

Surgical Conference, Washington Hospital: Common Surgical Dermatoses. Fremont, CA: March 5, 1991.

Medical Conference, Alexian Brothers Hospital: Dermatologic Unknowns. San Jose, CA: March 25, 1991.

Hospital Grand Rounds, Alexian Brothers Hospital: Melanoma. San Jose, CA: April 2, 1991.

Medical Conference, Washington Hospital: Dermatologic Manifestations of AIDS. Fremont, CA: February 28, 1992.

Family Practice Conference, Washington Hospital: Melanoma. Fremont, CA: March 19, 1992.

Pediatric Conference, Alexian Brothers Hospital: Acne Vulgaris. San Jose, CA: August 5, 1992.

Pediatric Conference, Alexian Brothers Hospital: Atopic Dermatitis. San Jose, CA: October 3, 1992.

Medical Conference, Alexian Brothers Hospital: Cutaneous Manifestations of Systemic Disease. San Jose, CA: April 26, 1993.

Medical Conference, Mount Zion Hospital/UCSF Medical Center: Cutaneous Manifestations of Systemic Disease. San Francisco, CA: May 14, 1993.

Medical Conference, Alexian Brothers Hospital: Acne Vulgaris. San Jose, CA: June 27, 1994.

Hospital Grand Rounds, Alexian Brothers Hospital: Geriatric Dermatology. San Jose, CA: August 30, 1994.

Medical Conference, Washington Hospital: Geriatric Dermatology. Fremont, CA: February 24, 1995.

Hospital Grand Rounds, Alexian Brothers Hospital: Geriatric Dermatology. San Jose, CA: August 8, 1995.

Hospital Grand Rounds, San Jose Medical Center: Common Dermatoses. San Jose, CA: August 24, 1995.

Hospital Grand Rounds, Alexian Brothers Hospital: Common Pediatric Dermatoses. San Jose, CA: June 11, 1996.

Medical Conference, Washington Hospital: Geriatric Dermatology. Fremont, CA: April 25, 1997.

Medical Conference, Washington Hospital: Dermatologic Unknowns. Fremont, CA: March 6, 1998.

Medical Conference, the Allergan Corporation: Tazorac and Its Uses in Psoriasis. Mountain View, CA: April 28, 1998.

Dermatology Residents Conference, Stanford University School of Medicine, Department of Dermatology: Unknowns. Palo Alto, CA: 3 times per year since 1998.

Obstetrical Conference, Washington Hospital: Common Dermatoses of Pregnancy. Fremont, CA, June 10, 1998.

Hospital Grand Rounds, Alexian Brothers Hospital: Androgenetic Alopecia and Other Forms of Diffuse Hair Loss. San Jose, CA: June 30, 1998

Internal Medicine Grand Rounds, Brookdale Hospital and the Mt. Sinai School of Medicine Department of Dermatology: Common Dermatoses for the Internist. Brooklyn, NY: June 15, 1999.

Pediatric Conference, Alexian Brothers Hospital: Atopic Dermatitis. San Jose, CA: December 10, 1999.

Medical Conference, San Jose Medical Group: Skin Cancer. San Jose, CA: September 12 and November 16, 2000.

Pediatric Conference, Washington Hospital: Common Pediatric Dermatoses. Fremont, CA: November 13, 2000.

Hospital Grand Rounds, Regional Medical Center: Dermatologic Unknowns. San Jose, CA: May 15, 2001.

Medical Conference, the Fujisawa Corporation: Protopic and Atopic Dermatitis. San Jose, CA: May 16, 2001.

Hospital Grand Rounds, Good Samaritan Hospital: Dermatologic Unknowns. Los Gatos, CA: June 20, 2001.

Medical Conference, the Fujisawa Corporation: Protopic and Atopic Dermatitis. San Jose, CA: May 16, 2001; Fremont, CA: June 13, 2001; Danville, CA: June 27, 2001; Monterey, CA: July 11, 2001; Salinas, CA: July 25, 2001; Palo Alto, CA: August 1, 2001; Mountain View, CA: August 15, 2001; Lafayette, CA: September 5, 2001.

Medical Conference, the Galderma Corporation: Acne Vulgaris, Moisturizers, and Melasma. Seattle, WA: February 5, 2002; Orem, UT: May 8, 2002; Central Valley Dermatological Society Meeting, Fresno, CA: May 21, 2002; University of California San Diego Grand Rounds, San Diego, CA: June 13, 2002.

Medical Conference, the Connetics Corporation: Vehicles. San Jose, CA: April 2, 2002.

Medical Conference, the Dermik- Aventis Corporation: Acne Vulgaris. Palo Alto, CA: July 22, 2002.

Medical Conference, The Fujisawa Corporation: Pediatric Dermatology. Stockton, CA, August 7, 2002

Medical Conference, The Galderma Corporation: Retinoids. Westlake Village, CA: August 14, 2002.

Medical Conference, the Fujisawa Corporation: Atopic Dermatitis. Palm Springs, CA: August 21, 2002.

Medical Conference, the Glaxo Smith Kline Corporation: Bacterial and Viral Skin Infections. Sunnyvale, CA: September 18, 2002.

Medical Conference, the Fujisawa Corporation: Pediatric Dermatology. San Jose, CA: October 2, 2002.

Medical Conference, the San Jose Medical Group Department of Pediatrics: Acne Vulgaris. San Jose, CA: November 6, 2002.

Medical Conference, the Allergan Corporation: Botox. Stockton, CA: November 13, 2002.

Medical Conference, The Montana State Dermatology Society: Vehicles and Moisturizers, Retinoids, Melasma, and Botox. Big Sky, Montana: January 31-February 2, 2003.

Medical Conference, O'Connor Hospital: Bacterial and Viral Skin Infections. San Jose, CA: April 22, 2003

Medical Conference, San Jose Medical Group Department of Pediatrics: Common Pediatric Dermatoses. San Jose, CA: May 7, 2003.

Medical Conference, The San Jose Medical Group Department of Internal Medicine: Bacterial and Viral Skin Infections. San Jose, CA: June 4, 2003.

Medical Conference, The Connetics Corporation: Vehicles. Mountain View, CA: June 18, 2003.

Medical Conference, Washington Hospital: Acne Vulgaris. Fremont, CA: June 20, 2003.

Medical Conference, The Aventis Corporation: Acne Vulgaris. San Jose, CA: July 16, 2003.

Medical Conference, The Aventis Corporation: Acne Vulgaris. Los Gatos, CA: July 23, 2003.

Medical Conference, The San Jose Medical Group, Department of Pediatrics: Common Pediatric Dermatoses. San Jose, CA: August 20, 2003

Medical Conference, The Siefel Corporation: Acne Vulgaris. Berkeley, CA: September 13, 2003.

Medical Conference, The Connetics Corporation: Vehicles. San Jose, CA: November 18, 2003.

Medical Conference, The Connetics Corporation: Vehicles. San Francisco, CA: December 3, 2003.

Medical Conference, The Connetics Corporation: Vehicles. Stockton, CA: December 10, 2003.

Medical Conference, San Jose Medical Center Family Practice
Residency Conference: Common Pediatric Dermatoses. San Jose,
CA: January 29, 2004

Pediatric Conference, Kaiser Foundation Hospital: Acne Vulgaris.
Oakland, CA: February 17, 2004.

Medical Conference, The Stiefel Corporation: Vehicles. Walnut Creek,
CA: February 24, 2004.

Pediatric Conference, The Feindale Corporation: Common Pediatric
Dermatoses. Fremont, CA: March 15, 2004.

Medical Conference, The Stiefel Corporation: 50 Pearls of Practice
Management. Seattle, WA: March 30, 2004

Medical Conference, The Sacramento Podiatric Society: Vehicles.
Sacramento, CA: April, 20, 2004.

Medical Conference, The Connetics Corporation: Vehicles. Walnut
Creek, CA: May 18, 2004.

Medical Conference, The Allergan Corporation: Retinoids. Denver,
CO: June 15, 2004.

Medical Conference, The Dermik-Aventis Corporation: Acne Vulgaris.
Fremont, CA: July 28, 2004.

Medical Conference, The Dermik-Aventis Corporation: Acne Vulgaris.
San Jose, CA: August 4, 2004.

Medical Grand Rounds, Regional Medical Center: Acne Vulgaris. San
Jose, CA: July 20, 2004.

Medical Grand Rounds, San Jose Medical Center: Acne Vulgaris. San
Jose, CA: August 19, 2004.

Medical Conference, The Dermik-Aventis Corporation: Acne Vulgaris.
San Jose, CA: September 15, 2004.

Medical Conference, The Fujisawa Corporation: Protopic. Fremont,
CA: October 7, 2004.

Medical Conference, The Dermik-Aventis Corporation: Acne Vulgaris.
Fremont, CA: October 20, 2004.

Medical Conference, The Dermik-Aventis Corporation: Acne Vulgaris.
Orinda, CA: November 10, 2004.

Medical Conference. The Fujisawa Corporation: Atopic Dermatitis.
San Jose, CA: December 8, 2004.

American Academy of Dermatology Meeting: Tazarotene Cream (0.1%) in Combination with Betamethasone Valerate Foam (0.12%) for Plaque Type Psoriasis. New Orleans, LA: February 18-22, 2005.

Pediatric Teleconference, the Pediamed Corporation: Tazorac and Acne. Fremont, CA : April 28, 2005.

Medical Conference, The Allergan Corporation: Retinoids. Calabasas, CA: May 10, 2005.

Pediatric Teleconference, The Pediamed Corporation: Tazorac and Acne. Fremont, CA: July 12 & 14, 2005.

Medical Conference, the Allergan Corporation: Retinoids. Walnut Creek, CA June 11, 2005.

National Eczema Association Conference: Hand Dermatitis. San Jose, CA: August 6, 2005.

Poster Session, American Academy of Dermatology Summer Meeting: Combination of Clindamycin/Tretinoin Hydrogel for the Treatment of Acne Vulgaris in 1247 Adolescents. Chicago, Illinois: July 14-19, 2005.

Poster Session, American Academy of Dermatology, Summer Meeting: Modern Combination Treatments for Psoriasis Using Acetretin. Chicago, Illinois: July 14-19, 2005.

Medical Conference, The California Association of Physicians' Assistants: Acne Vulgaris. Sacramento, CA. October 20, 2005.

Medical Conference. The Dermik Corporation: Onychomycosis. Fremont, CA. November 17, 2005.

Training Conference. The Physicians Interaction with the Pharmaceutical Representative. Irvine, CA: January 4, 2006; May 5, 2006.

Medical Conference, The Dermik-Aventis Corporation: Acne Vulgaris. Fremont, CA January 25, 2006.

Poster Session, American Academy of Dermatology, Annual Meeting: Tolerability and Preference of Two Benzoyl Peroxide/Clindamycin gels

in Combination with Tretinoin .025% cream in Adult Female Acne Patients. San Francisco, CA March 3-7, 2006.

Medical Conference, The Warner Chilcott Corporation: The Use of Taclonex in Psoriasis. Santa Rosa, CA: June 14, 2006.

Medical Conference, The Warner Chilcott Corporation: The Use of Taclonex in Psoriasis. Reno, Nevada: June 25, 2006.

Medical Conference, The Warner Chilcott Corporation: The Use of Taclonex in Psoriasis. Bakersfield, CA: September 19, 2006.

Medical Conference, The Warner Chilcott Corporation: The Use of Taclonex in Psoriasis. Fresno, CA: September 20, 2006.

Medical Conference, The Warner Chilcott Corporation: The Use of Taclonex in Psoriasis. Napa, CA: October 4, 2006.

Medical Conference, The Connetics Corporation: The Use of Foams in Pediatrics. San Jose, CA: October 18, 2006

Medical Conference, The Connetics Corporation: The Use of Foams in Pediatrics. Sacramento, CA: November 15, 2006

Training Conference, The Allergan Corporation: Interacting with the Dermatologist. Santa Ana, CA: September 23, 2006

American Academy of Dermatology Meeting: Tazarotene plus Clindamycin in the Treatment of Acne Vulgaris: A Multicenter Investigation – Blind Randomized Parallel Group Study. Washington, D.C.: February 2-7, 2007.

Winter Clinical Meeting: A Comparison of Two Benzoyl Peroxide 5%/Clindamycin 1% Topical Gels Used Once Daily in the Management of Acne Vulgaris. Hawaii, January 15, 2007.

Tazarotene Training Meeting, the Allergan Corporation. Tazarotene Tolerability. Dallas, TX: June 6, 2007.

Training Meeting, the Stefel Corporation. Physicians and Pharmaceutical Representatives. Atlanta, Georgia: June 15, 2007.

Medical Conference, The Skin Medica Corporation. Desonate Gel. Mountain View, CA: June 19, 2007.

Tazarotene Training Meeting, the Allergan Corporation. Tazarotene Tolerability. Napa, CA: July 15, 2007

Training Meeting, the Pharmaderm Corporation. Physicians and Pharmaceutical Representatives; Dermatology 101; Fungal Infections. Atlanta, Georgia: September 16, 2007.

Training Meeting, the Stiefel Corporation. Soriatane. Dallas, Texas: October 17, 2007.

The Skin Medica Corporation. Desonate and the History of Topical Steroids. San Francisco, CA: January 15, 2008.

The Obagi Corporation. Acne and Clenziderm. Palo Alto, CA: May 14, 2008.

The Stiefel Corporation. Training meeting. Product Benefits and Competitive Landscape. Atlanta, GA: August 12, 2008.

The Galderma Corporation. Acne Vulgaris. San Jose, CA: October 5, 2008.

The Warner Chilcott Corporation. Doryx. Seattle, WA: January 27, 2009.

Training Session, The Stiefel Corporation. Atlanta, GA: February 11, 2009.

The American Association of Physicians of Indian Origin. Acne Vulgaris. Newark, CA: February 13, 2009.

The Warner Chilcott Corporation. Doryx. San Francisco, CA: March 5, 2009.

The Galderma Corporation. Acne Vulgaris. Fresno, CA: March 25, 2009.

The Galderma Corporation. Acne Vulgaris. Pasadena, CA: April 1, 2009.

Washington Hospital Grand Rounds. The Rational Use of Topical Steroids. Fremont, CA: April 8, 2009.

Regional Medical Center of San Jose Grand Rounds. The Rational Use of Topical Steroids. San Jose, CA: May 5, 2009.

The Galderma Corporation. Vectical. San Jose, CA: May 6, 2009.

The Warner Chilcott Corporation. Doryx and Taclonex. San Jose, CA: May 20, 2009.

Summer AAD Poster 2009. Comparing Noxel solubilized benzoyl peroxide gel with benzoyl peroxide/clindamycin. Final data from a multicenter investigation blind randomized study. Boston, MA: July 29 - August 2, 2009.

Regional Medical Center of San Jose Grand Rounds. Geriatric Dermatology. San Jose, CA: September 23, 2009.

American Academy of Dermatology Summer Meeting. Evaluation of a Blue Light Treatment System for the Self-Treatment of Mild-Moderate Acne. Chicago, IL. July, 2010

Fall Clinical Dermatology Meeting. Clinical Evidence for the Role of a Topical Anti-inflammatory Agent in Comedonal Acne: Findings from a Study of Dapsone 0.5% Gel in Combination with Tazarotene 0.1% Cream in Patient's with Acne Vulgaris. Las Vegas, NV: October 8-11, 2010.

Tria Beauty Web Conference. A Novel Over the Counter Blue Light System for Treating Acne. Dublin, CA December 10, 2010.

World Congress of Dermatology. Evaluation of a Blue Light Treatment System for the Self Treatment of Mild to Moderate Acne. Seoul, Korea: May 2011.

Orlando Dermatology Aesthetic and Clinical Conference. Evaluation of a Blue Light Treatment System for the Self Treatment of Mild-Moderate Acne. Orlando, FL: January 14-17, 2011.

Orlando Dermatology Aesthetic and Clinical Conference. Tolerability in Asian Skin of a Consumer Blue Light Device for the Self Treatment of Acne Vulgaris. Orlando, FL. January 2011.

Maui Dermatology Conference. Evaluation of a Blue Light Treatment System for the Self Treatment of Mild-Moderate Acne. Maui, Hawaii: February 23-27, 2011.

Maui Dermatology Conference. Tolerability in Asian Skin of a Consumer Blue Light Device for the Self Treatment of Acne Vulgaris. Maui, Hawaii. February 2011.

Efficacy and Safety of a Novel Dual Resurfacing Product that Combines the Benefits of Manual Microdermabrasion and Chemical Peeling.
AAD summer meeting, 8/3-8/7/2011.

The Stefel IGSK Corporation, Veltin Gel. San Jose, CA. November 16, 2011.

The American Academy of Dermatology Meeting. Tolerability in Asian Skin of a Consumer Blue Light Device for the Self Treatment of Acne Vulgaris. San Diego, CA: March 17, 2012.

Skin of Color Seminar Series. Tolerability in Asian Skin of a Consumer Blue Light Device for the Self Treatment of Acne Vulgaris. Las Vegas, NV: June 2-3, 2012.

Skin of Color Seminar Series. Evaluation of a Blue Light Treatment System for the Self Treatment of Mild-Moderate Acne. Las Vegas, NV: June 2-3, 2012.

Medical Conference, the Leo Pharma Corporation. Picato. San Jose, CA: June 5, 2012.

Medical Conference, the Leo Pharma Corporation. Picato. Fremont, CA: July 10, 2012.

The Allergan Corporation. The Life of a Dermatologist. Irvine, CA: September 7, 2012.

Medical Conference, the Leo Pharma Corporation. Picato. Redwood City, CA: December 10, 2012.

Medical Conference, the Merz Corporation. Tinea Pedis. San Jose, CA: January 8, 2013.

Medical Conference, the Leo Corporation: Picato. Monterey, CA: March 19, 2013

American Society for Laser Medicine & Surgery. Evaluation of a Compact Home VK 1440 nm Non-Ablative Fractional Laser To treat Periorbital Wrinkles. Las Vegas, NV: April 25, 2015.

Stanford University Department of Dermatology. Dermatologic Unknowns. Redwood City, CA: March 31, 2015.

Stanford University Department of Dermatology. Dermatologic Unknowns. Redwood City, CA: October 6, 2015.

Regional Medical Center, Weekly Medical Staff Lecture. Dermatologic Unknowns. San Jose, CA: May 5, 2015.

Regional Medical Center Weekly Medical Staff Lecture. Common Pediatric Dermatitis. San Jose, CA: September 29, 2015.

Association of Dermatology Administrators and Managers Annual Meeting. How to Integrate Clinical Trials Into a Medical Practice. San Francisco, CA: March 20, 2015.

One Medical Clinic. Dermatologic Unknowns. San Jose, CA: July 13, 2016.

Family Practice Residency Program, O'Connor Hospital/Stanford University. Dermatologic Unknowns. San Jose, CA: August 16, 2016.

Family Practice Residency Program, O'Connor Hospital/Stanford University. Acne Vulgaris. San Jose, CA: September 13, 2016.

Washington Hospital. Sun-Beauty and the Beast. Fremont, CA: August 11, 2016.

One Medical Clinic. Common Adult Dermatoses. San Jose, CA: September 11, 2016.

University of California Davis Dermatology Residency Program. Vehicles. Sacramento, CA: December 15, 2016

Family Practice Residency Program, O'Connor Hospital/Stanford University. Common Pediatric Dermatitis. San Jose, CA: February 26, 2017.

Dermatology Residency Program, Stanford University Department of Dermatology. Dermatologic Unknowns. Redwood City, CA January 18, 2017.

Dermatology Residency Program, Stanford University Department of Dermatology. Vehicles. Palo Alto, CA. February 28, 2017.

Verity Medical Foundation Medical Conference. Dermatologic Unknowns for the Primary Physician. San Jose, CA. June 20, 2017.

Washington Hospital. The Sun-Beauty or the Beast. Fremont, CA. May 24, 2017.

North East Medical Services. Dermatologic Unknowns. San Jose, CA: March 29, 2018.

Family Practice Residency Program Verity Hospital/Stanford University. Common Pediatric Dermatoses. San Jose, CA: April 17, 2018.

North East Medical Services. Acne Vulgaris. San Jose, CA: September 6, 2018.

Mind and Body Healing Retreat. Natural Treatments in Dermatology. Mount Madonna Center, Watsonville, CA: September 8, 2018.

North East Medical Services. Rational Use of Topical Steroids. San Jose, CA. November 14, 2018.

Verity Medical Foundation. Rational Use of Topical Steroids. San Jose, CA: November 21, 2018.

The Pfizer Corporation. Eucrisa. Menlo Park, CA: December 6, 2018.

The Mayne Corporation. Fabior. Milpitas, CA: April 9, 16, 30, 2018.

Regional Medical Center. Bacterial, Fungal, Viral and Parasitic Infections. San Jose, CA: April 23, 2019.

**CLINICAL
RESEARCH
EXPERIENCE:**

2019 – Principal Investigator in two phase 3 prurigo nodularis trials, three phase 3 topical psoriasis trials, three phase 3 systemic psoriasis trials, four phase 2/3 systemic atopic dermatitis, three phase 3 topical atopic dermatitis, one phase 1/2 rosacea topical trials, one phase 2 topical rosacea trial, one phase 2 toxin trial, one phase 3 topical vitiligo trial, and one phase 3 oral alopecia areata trial.

2018 – Principal Investigator in three phase 3 acne trials, two phase 2 acne trials, two phase 2 topical psoriasis trials, two phase topical psoriasis trials, three phase 3 systemic psoriasis trials, two phase 2 systemic atopic dermatitis trials, three phase 3 systemic atopic dermatitis trials, two phase 3 rosacea trials, and one phase 2 rosacea trial.

2017 – Principal investigator in two phase 3 psoriasis trials, two phase 2/3 wrinkle trials, two phase 3 actinic keratosis trials, two phase 3 atopic dermatitis topical trials, two phase 2-3 systemic atopic dermatitis trials.

2016 – Principal investigator in five phase 3 acne trials, two phase 3 systemic psoriasis trials, two phase 3 topical psoriasis trials, one phase 3 scalp psoriasis trial, one phase 3 atopic dermatitis trial, two phase 2/3 actinic keratoses trials, two phase 3 rosacea trials, two phase 3 onychomycosis trials, and two phase 3 tinea pedis trials.

2015 – Principal investigator in five phase 3 oral acne trials, three phase 3 topical and systemic atopic dermatitis trials, four actinic keratosis phase 3 trials, two systemic and two topical phase 3 psoriasis trials, one phase 2 hyperhidrosis trials, two phase 3 rosacea trials.

2014 – Principal investigator in four phase 3 acne trials, one phase 2 oral acne trials, four phase 3 systemic psoriasis trials, two phase 3 topical psoriasis trials, three phase 3 atopic dermatitis trials – topical and systemic, one phase 2 pruritus trial, one phase 3 hyperhidrosis trial, four phase 3 actinic keratosis trials, one phase 3 erythema trial, one phase 3 rhytide trial, and two phase 3 rosacea trials.

2013 – Principal Investigator in four phase 3 acne trials, two phase 3 systemic psoriasis trials, one phase 3 topical psoriasis trial, one phase 3 systemic atopic dermatitis trial, one phase 2 topical atopic dermatitis trial, two phase 3 actinic keratosis trial, one phase 3 tinea pedis trial, two phase 3 actinic keratosis trials, one phase 3 pruritis oral trial, and one phase 3 hair growth trial.

2012 – Principal investigator in three acne phase 3 trials, two phase 3 systemic psoriasis trials, two phase 2 atopic dermatitis trials, one phase 3 seborrheic dermatitis trial, one phase 3 actinic keratosis trial and two phase 3 tinea pedis trials. Met or exceeded all targets except in the seborrheic dermatitis trials where our site reached 80% of the target.

2011 – Principal investigator in three phase 3 and two phase 4 acne trials, two phase 3 psoriasis trials, one phase 3 onychomycosis trial, one phase 3 tinea pedis trial, one phase 3 tinea cruris trial. Met or exceeded enrollment targets except in the tinea cruris trial.

2010 – Principal investigator in three phase 3 and two phase 4 acne trials, two phase 3 psoriasis trials, one phase 4 chemical peel trial and one phase 4 erythema trial.

2009- Principal investigator in two phase 3 topical actinic keratosis trails, four phase 3 and 4 acne vulgaris trials, five phase 3 and 4 systemic and topical psoriasis trials, one phase 2 oral onychomycosis trial, one phase 4 cosmetic topical trial, one phase 2 topical atopic dermatitis trial, and two phase 3 and 4 topical and oral rosacea trials.

2008 – principal investigator three phase 3, and three phase 4 acne trials; two phase 3 psoriasis trials; three phase 3 actinic keratoses trials; two phase 3 onychomycosis trials; and one phase 3 genital wart trial. All ongoing or completed, and met targets except in the genital wart trial where our site reached 65% of our target.

2007 – principal investigator for 4 phase 4 topical acne trials, one phase 3 actinic keratosis trial, one phase 3 topical psoriasis trial, one phase 3 oral onychomycosis trial.

2006 – principal investigator for 4 phase 4 topical acne trials, one phase 3 topical actinic keratosis trial, one phase 3 topical psoriasis trial, and one phase 3 oral onychomycosis trial. Met or exceeded enrollment targets.

2005 - principal investigator for two Phase III trials for atopic dermatitis products, and two acne products-ongoing

2004 - principal investigator for phase III trials for a topical psoriasis product , and three topical combination acne products- met or exceeded enrollment targets.

2003 - 2004 - principal investigator for a Phase III trial for a topical antifungal, and a phase IV trial for a topical agent for actinic keratosis. Met enrollment targets quickly.

2003 - principal investigator for a Phase III trial for a topical combination acne product. Met enrollment targets quickly (70 patients) and acted as a rescue site for sites that could not enroll enough patients.

1996 - principal investigator for a Phase IV trial for an oral antifungal trial. Met enrollment target quickly (20 patients).

1987 - 1990 - subinvestigator for three Phase III trials for topical steroid and antifungal preparations.

**HOSPITAL STAFF
PRIVILEGES:**

Washington Hospital, Fremont, CA
Regional Medical Center Hospital, San Jose, CA

**COMMUNITY
ACTIVITIES:**

Chairperson Patron Fund Committee, The American Association of Physicians of Indian Origin, 2003-present.

Editor, The Newsletter of the American Association of Physicians of Indian Origin, 2003-2004.

President, The American Association of Physicians of Indian origin, 2002-2003, representing over 700 physicians of East Indian origin in Northern California.

Vice President, The American Association of Physicians of India Origin 2001-2002.

Chairperson, CME Committee, The American Association of Physicians of Indian Origin, 2001-2002.

Health Fair Committee, The American Association of Physicians of Indian Origin, 1991-2000.

Secretary, The American Association of Physicians of Indian Origin, 1993 - 1994, 2000-2001.

Treasurer, The American Association of Physicians of Indian Origin, 1991 - 1993.

Lecturer on skin cancer prevention: Washington Hospital, to the City of San Jose employees, the Rotary, Lions and Kiwanis Clubs, Milpitas High School, and corporations such as PG&E, Quantum, Lifescan, Sun

Microsystems, Varian and Associates, Johnson and Higgins, Applied Materials, Apple, 3-Com, FMC, Novell, Club Sport Athletic Club, IndoAmerican Community Center, Temple Beth Torah – Fremont.

Chairperson, Skin Cancer Screening for Southern Alameda County, American Academy of Dermatology, 1991, 1992, 1993, 1994, 1997, 2004, 2005, 2006.

Lecturer on Atopic Dermatitis and treatment with new topical immune modulators: to the public at multiple sites in the Bay Area in 2001-2002.

Member of the Board of Trustees, The American Association of Physicians of Indian Origin, 2004-present.

Skin cancer screening at various health fairs including those Sponsored by the American Association of Physicians of Indian Origin, the Livermore Hindu Temple, the Santa Clara Department Of Social Services.